The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Export 11032 results:
[ Author(Desc)] Title Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., Mathew H., & Mantzoros C. S. (2015).  Irisin: A true, circulating hormone.. Metabolism. 64(12), 1611-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2012).  Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease.. Metabolism. 61(6), 755-8.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Polyzos, S. A., Kountouras J., Goulas A., Papakonstantinou E., & Papaioannidou P. (2020).  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.. Hepatobiliary Surg Nutr. 9(1), 73-76.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2020).  Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.. Metabolism. 104, 154144.
Polyzos, S. A., Kountouras J., Zavos C., & Tsiaousi E. (2010).  The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.. Diabetes Obes Metab. 12(5), 365-83.
Polyzos, S. A., Goulis D. G., Giouleme O., Germanidis G. S., & Goulas A. (2022).  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Polyzos, S. A., & Margioris A. N. (2018).  Sarcopenic obesity.. Hormones (Athens). 17(3), 321-331.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis. Current Medicinal Chemistry. 30,
Polyzos, S. A., Anastasilakis A. D., Makras P., & Terpos E. (2011).  Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.. Exp Clin Endocrinol Diabetes. 119(9), 519-24.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism. 96, iii-v.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance.. Clinics (Sao Paulo). 66(5), 911-2.
Polyzos, S. A. (2012).  Editorial: adiponectin in health and disease: current evidence and therapeutic perspectives.. Curr Med Chem. 19(32), 5425-6.
Polyzos, S. A., Anastasilakis A. D., Litsas I., Efstathiadou Z., Kita M., Arsos G., et al. (2010).  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.. J Bone Miner Metab. 28(6), 706-12.
Polyzos, S. A., Kountouras J., Mavrouli M., Katsinelos P., Doulberis M., Gavana E., et al. (2019).  Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease.. Exp Clin Endocrinol Diabetes.
Polyzos, S. A., Kountouras J., & Anastasilakis A. D. (2021).  Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis.. Metabolism. 121, 154818.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2013).  Helicobacter pylori Infection and insulin resistance.. Helicobacter. 18(2), 165-6.
Polyzos, S. A., Makras P., Tournis S., & Anastasilakis A. D. (2019).  Off-label uses of denosumab in metabolic bone diseases.. Bone. 129, 115048.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.